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Abstract: In this TFG we review the Linear-Quadratic (LQ) model of cell survival to ionizing
radiation and the concept of biological effective dose (BED). We will explain the effect of dose
protraction and incomplete damage repair, cell repopulation, the kind of radiation and oxygenation,
and how to introduce them into the LQ model and the BED.
I. INTRODUCTION
The aim of radiotherapy, like chemotherapy or surgery,
is to eradicate all the malignant (cancer) cells that form
a tumour while keeping as low as possible the damage to
the healthy tissues. There are many variables that can
be taken into account to make radiotherapy more precise
and to predict better the outcome of the treatment. The
most important ones are the effect of incomplete repair
of radiation damage when the delivery of absorbed dose
is protracted (i.e. extended in time), cell repopulation,
the relative biological effectiveness and the presence of
oxygen.
II. GENERAL CONCEPTS
A. Lethal and sublethal damages
Ionizing radiations may produce substantial damage to
the irradiated cells. The damages that relate better to
cell killing are the ones inflicted to the DNA, although
not all lesions produce the death of the cell. Some can be
repaired and the cells may continue their cycle even with
mutations. We will define two kinds of lethal damages:
• Type A: the lethal damage is inflicted when a sin-
gle ionizing event produces a double strand break
in the DNA. The amount of damage (yield) is pro-
portional to absorbed dose, yA ∝ D, but indepen-
dent of absorbed dose rate and exposure time [1–5]
(Fig. 1a).
• Type B: the lethal damage is the result of indepen-
dent sub-lethal damages induced by separate ion-
izing events. The yield is proportional to absorbed
dose square, yB ∝ D2, and in this case it also de-
pends on the dose rate and the exposure time. If
the absorbed dose rate is low enough and the time
between events increases, the first sub-lethal dam-
age can be repaired before the second one is in-
flicted and, therefore, they cannot interact to pro-
duce a lethal lesion [1–5] (Fig. 1b).
FIG. 1: (a) Type A: yA = αD. (b) Type B: yB = βGD
2.
B. Linear-Quadratic model
The Linear-Quadratic (LQ) model is nowadays widely
used to design radiotherapy schedules as it provides an
explanation to the fact that tumours and healthy tissues
react differently to irradiation and that different sched-
ules may result in a sparing effect for the healthy tissues
while still controlling the tumour [3]. Also, its predictive
properties are well documented and there is no evidence
of it leading to significant overdosing or underdosing [6].
The equation that predicts the survival probability of
a cell after being irradiated with a total absorbed dose
D is
s(D) = e−(yA+yB) = e−αD−βGD
2
, (1)
where the yields of lethal damages of types A and B are
αD and βGD2, respectively. The constants α and β are
specific to the cell line and ionizing radiation. The Lea–
Catcheside (LC) factor G modifies the βD2 term, being
G = 1 for a single acute irradiation and 0 < G < 1 for
protracted radiotherapy, and it depends on the damage
repair rate µ [7]; the LC factor will be addressed in more
depth in section III.
C. Biological Effective Dose
The biological effective dose (BED) is defined as the
theoretical total absorbed dose required to produce a
certain effect using an infinite number of infinitesimally
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small absorbed dose fractions or with an infinitesimal ab-
sorbed dose rate [8]. It is a useful concept to assess the
biological effect of an irradiation and to compare two dif-
ferent schedules of radiotherapy. The BED is
BED = D × RE, RE = 1 + type A damage
type B damage
, (2)
where D is the total absorbed dose and RE (relative ef-
ficiency) is a factor that considers the biological parame-
ters and how the irradiation is delivered [1, 2]. Using the
LQ model the expression of the BED becomes [2, 7]
BED = − ln s(D)
α
= D
(
1 +
GD
α/β
)
. (3)
This definition shows that we only need to know two pa-
rameters, namely the α/β ratio and the LC factor, to be
able to predict the effect of a certain irradiation strategy.
As will be explained below, α/β may have significant
differences between tumour and normal tissues, and G is
related to incomplete damage repair.
D. The α/β ratio
This ratio quantifies the relation between intrinsic ra-
diosensitivity (α) and the potential sparing effect (β)
[2] (Fig. 2). Hence, it is an indicator of the sensitiv-
ity to changes in fractionation or absorbed dose rate
of each tissue or tumour. α/β can be determined by
plotting, for a given effect E = − ln s(D), the recip-
rocal of the number of fractions (1/n) against the ab-
sorbed dose per fraction (d = D/n) and fitting a parabola
1/n = (α/E)d+ (β/E)d2 [8].
FIG. 2: Effect of an irradiation according to the LQ
model (taking G = 1). At D = α/β the contributions of
both types of damages are equal.
Considering this ratio we can distinguish two groups:
• High α/β ratio (7–20 Gy), typical of early-
responding tissues and most tumours [8]. Tissues
with a high α/β ratio are fast proliferating [7]. The
surviving fraction of these tissues after irradiation
is not influenced by changes in the schedule pro-
vided that the overall time remains the same [9].
• Low α/β ratio (0.5–6 Gy) is common in late-
responding tissues and some tumours such as
melanomas, sarcomas and early-stage prostate can-
cer [8]. The surviving fraction of these tissues is in-
fluenced by changes in fractionation, and they can
be spared if D is delivered in small absorbed dose
per fraction [9, 10].
III. DOSE PROTRACTION
Cells can repair the sub-lethal damage caused by irra-
diation if given enough time (between 6 hours and 1 day
[8]), and therefore the amount of lesions decreases. This
damage repair can be modelled as an exponential [5, 7],
R(t) = R0 e
−µt, (4)
where R(t) is the amount of damage at time t and µ is
the damage recovery constant; typical repair half times
span from 0.5 h to 3 h, hence µ ∼ 1 h−1 [3]. Considering
the repair as an exponential process is an oversimplifica-
tion and probably it is better described as a combination
of exponentials, but we will use the former as a first ap-
proximation. If the repair of the sub-lethal damages is
successful before another irradiation produces more sub-
lethal lesions (Fig. 3), the cell survives. This recovery
can happen between radiotherapy sessions or during the
irradiation if the absorbed dose rate is low enough. To in-
troduce the possibility of incomplete repair into the LQ
model we add the LC factor G that modifies the βD2
component. Its general expression is
G =
2
D2
∫ T
0
D˙(t) dt
∫ t
0
e−µ(t−t
′) D˙(t′) dt′, (5)
where D˙(t) is the dose rate, D the total absorbed dose
and T is the overall treatment time. This factor takes
values 0 ≤ G ≤ 1, being G = 1 for a single acute dose [7].
In the following subsections we will give the expressions
for a few common radiotherapy modalities that we have
derived from the general definition.
FIG. 3: Time line: the first sub-lethal lesion is produced
at t and the second one at t′ > t. There is a time interval
t′ − t during which the cell may repair the first lesion
before it can interact with the second one.
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A. High-dose-rate fractions
D is split into n fractions of absorbed doses d = D/n,
each delivered in a few minutes (high dose-rate) by an
external photon or electron beam generated by a linac.
The conventional schedule is to deliver fractions of about
2 Gy, 5 times per week for about 6 weeks [10] (the total
absorbed dose and therefore the overall time depends on
the tumour that has to be controlled). Now the LC factor
takes the form [6, 10]
G =
1
n
[
1 +
2
n
θ
1− θ
(
n− 1− θ
n
1− θ
)]
; θ = e−µ∆T .
(6)
When the time between fractions ∆T is large enough
θ → 0 so that [6]
G =
1
n
and BED = D
(
1 +
d
α/β
)
. (7)
B. Continuous low dose rate
The absorbed dose is delivered continuously, during
hours or days, either with an external radiation beam
(teletherapy) or with an encapsulated radioactive source
(brachytherapy) (e.g. using temporary implants such as
192Ir [23] seeds in the form of ribbons or strands to treat
breast and head & neck tumours [11]). An absorbed dose
rate ∼ 0.05 Gy/h (equivalent to fractions of 2 Gy) allows
repair to take place during irradiation [7, 8]. Considering
that the decay half life of the radionuclide is much greater
than the overall time T , the absorbed dose rate is simply
D˙(t) = D/T and the LC factor becomes [7]
G =
2
µT
(
1− 1− e
−µT
µT
)
. (8)
When T is long [2, 4]
G =
2
µT
and BED = D
(
1 +
2D
µT (α/β)
)
. (9)
C. Exponentially decaying dose rate
When a radioactive source is implanted in the body for
a long enough time, comparable or greater than the half
life of the radionuclide, the absorbed dose rate cannot be
considered constant. These sources can be either encap-
sulated, like in permanent brachytherapy implants (e.g.
125I [24] seeds to treat prostate and brain tumours [12]),
or unencapsulated. The latter are used in targeted radio-
therapy, also called molecular radiotherapy, in which a
radionuclide is attached to a biomolecule that selectively
delivers it to the tumour (e.g. 131I-mIBG [25] to treat
pheocromacytomas or neuroblastomas [13]). A particular
case of targeted radiotherapy is radio-immunotherapy, in
which the molecular vehicle is an antibody [14] (e.g. 90Y-
ibritumomab tiuxetan [26] to treat non-Hodgkin lym-
phoma [14]).
In these modalities D˙(t) decreases exponentially with
decay constant λ from an initial absorbed dose rate
D˙(0) to a smaller value (or 0, if left a long enough
time) [2]. Given that its time evolution is given by
D˙(t) = D˙(0) e−λt we have
D =
D˙(0)
λ
(
1− e−λT ) (10)
and the LC factor takes the form
G =
2λ2
µ− λ
A−B
C2
(11)
with [2]
A =
1− e−2λT
2λ
,B =
1− e−(µ+λ)T
µ+ λ
,C = 1− e−λT . (12)
When the radioactive source is allowed to decay com-
pletely (T →∞) we have D = D˙(0)/λ and then [3, 4]
G =
λ
µ+ λ
, BED =
D˙(0)
λ
(
1 +
D˙(0)
(µ+ λ) (α/β)
)
.
(13)
IV. REPOPULATION
The tumours’ response to irradiation is to grow (which
they do in a disorganized manner, forming different nod-
ules [10]). This growth has been modelled in many ways,
being the simplest one to consider the increase in number
of cells as an exponential
V (t) = V0 e
γT , (14)
where γ = ln 2/TD and TD is the duplication time [7, 10]
(Fig. 4a). However, tumours slow down their growth rate
as they get bigger because the distribution of nutrients
within the tumour changes and produces hypoxic zones
and necrotic zones in the center (Fig. 4b). As a conse-
quence, Eq. (14) does not fit the experimental data when
the tumours get big. The reduction in the growth rate
can be described by the Gompertz model
V (t) = V0 e
A(1−e−at), (15)
where A and a are adjustable parameters (Fig. 4a). This
model fits better the data than the exponential, but it
predicts a maximum volume which contradicts the evi-
dence [7, 8].
To a first approximation, to account for repopulation
in the BED, we will use the exponential model, although
as already mentioned it does not always fit the data and,
therefore, it will be an oversimplification.
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Notice that for late responding tissues, which are
slowly proliferating, no factor to describe repopulation
needs to be added [8, 15]. Repopulation will be included
in the BED (for fast proliferating tissues or tumours)
by adding a term that decreases the effectiveness, as it
counteracts the cell killing [2, 15]
BED = D × RE− RF, RF = γ
α
T. (16)
FIG. 4: (a) Models of tumour proliferation (b) tumour
structure (taken from [7]).
V. RELATIVE BIOLOGICAL EFFECTIVENESS
The linear energy transfer (LET) is the energy trans-
fered per unit length by the ionizing radiation. In the
case of charged particles it can also be defined as the re-
stricted linear electronic stopping power, as it is the elec-
tronic stopping power (S = −dE/dx) minus the mean
sum of the kinetic energies of secondary electrons greater
than a preselected value, usually 100 eV [16].
Conventional radiotherapeutic treatments use radia-
tions with low LET such as photons or electrons. Low
LET radiations produce ionizations (and therefore dam-
age) far apart form each other [8, 17], hence it is likely
that they generate more single strand breaks (repairable)
than double strand breaks (prone to result in lethal dam-
age) (Fig. 5a). On the other hand, high LET radiations
(e.g. α particles, neutrons) produce ionizations closer to-
gether and, as the damages are nearer from each other,
it is more probable that they cause double strand breaks
in the DNA and, as a consequence, more lethal damages
[3, 4, 17] (Fig. 5a).
The Relative Biological Effectiveness (RBE) is intro-
duced to take into account the different LETs. The RBE
is defined as the experimentally determined ratio of ab-
sorbed doses required to produce a given degree of cell kill
(RBEx−rays = 1 by convention) [3, 4]. The RBE maxi-
mizes when using low absorbed dose rates and, therefore,
to incorporate it into the BED we merely have to replace
the 1 in Eq. (3) (and Eqs. deduced from it) with this
factor [3, 4]. For instance, Eq. (13) is now written as
BED =
D˙(0)
λ
(
RBEmax +
D˙(0)
(µ+ λ) (α/β)
)
. (17)
This equation with RBEmax = 5 is adopted when
223Ra
[27] is used to treat bone metastases [18].
VI. OXYGEN
Oxygen is a radiosensitizer, which means that well-
oxigenated (oxic) cells are more sensitive to radiation
than hypoxic cells. This is because the presence of oxy-
gen reacts with H• free radicals
H• +O2 → HO•2;
{
HO•2 + HO
•
2 → H2O2 + O2
HO•2 + H
• → H2O2
causing a decrease of H• free radicals , which prevents the
recombination of radicals OH• allowing them to interact
with the DNA inducing damages. It may also capture
electrons preventing from recombining with ions or even
forming new radicals
e−ac +O2 → O−2 ; O−2 + H2O→ H2O• + HO−.
Or it can interact with organic radicals producing toxic
substances [7, 10]
R• +O2 → ROO•;
{
ROO• + R′H→ ROOH + R′•
ROO• + R′ → ROOR′.
The effect of ionizing radiation on oxic and hypoxic
cells is quantified by the oxygen enhancement ratio
(OER), which is the ratio of the absorbed doses required
in hypoxic to oxic conditions to achieve the same bio-
logical effect (a specified survival fraction s0, e.g. 10
−2)
[19, 20] (Fig. 5b) [8]
OER =
D(s0,hypoxic)
D(s0, oxic)
. (18)
Owing to their rapid growth, tumours typically contain
both oxic and hypoxic cells, the surviving fractions of
each type being different. Using the LQ model, oxic cells
will follow Eq. (1) [20, 21] whereas for hypoxic cells [20]
s(D) = exp
(
− α
OER
D − β
OER
GD2
)
. (19)
Because of this effect, the fractionation of the treatment
has another advantage: between fractions the hypoxic
cells may be re-oxygenated, making them more sensitive
to radiation and therefore more likely to be killed in the
next fraction [17, 20].
FIG. 5: Effects of (a) LET and (b) oxygen.
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VII. CONCLUSIONS
The LQ model and the BED concept admit, at first,
very simple expressions that only depend on the α/β
ratio. Nevertheless, they adapt rather well to the ex-
perimental data and allow us to compare radiotherapy
treatments. As we contemplate more aspects that may
influence the outcome of the treatment (such as the ef-
fect of time in the cells, i.e. that they may repair sub-
lethal damage and/or reproduce, the kind of radiation
used or the presence of oxygen) the expressions become
more complicated because new parameters (µ, γ, RBE
and OER, respectively) are introduced which can be dif-
ficult to know in a precise way.
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